Content matching 'cell therapy approval'
Cell therapy weekly: Bioethical framework for therapeutic gene editing released
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin
Cell therapy weekly: FDA indicates more guidance is to come on cell therapy manufacture
Cell therapy weekly: Positive results from regenerative tissue clinical trial for deep, partial-thickness thermal burns
Latest developments compiled from 01 – 31 December 2014
Supporting the FDA’s tougher stance on unproven cell therapies: an interview with Massimo Dominici
Latest developments compiled from 1 October until 30 November 2014
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it. In this interview with The Life Sciences Report, Vertès talks about some of the stem cell names he knows well, and draws comparisons investors can bank on.